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To the Editor:
Despite progress in tuberculosis (TB) control, the response to the multidrug- resistant (MDR) TB and
extensively drug-resistant (XDR) TB epidemic continues to be limited. The proportion of MDR-TB patients
who successfully completed treatment varied from 44% (Eastern Mediterranean Region) to 58% (South-
East Asia Region) [1]. Overall, treatment success was 48%, while 28% of cases were reported as lost to
follow-up or had no outcome information [1]. The Global Plan’s target for 2015 of achieving at least 75%
treatment success in MDR-TB patients was only reached by 30 out of 107 countries [1].
In the present paper, we evaluated the treatment outcomes of M/XDR-TB patients in Portugal. Patients
with pulmonary TB resistant to isoniazid and rifampin, who started treatment at some point between
January 2000 and December 2008, were selected from the national database, which integrates the data from
the mandatory registration of TB cases. The evaluation of treatment outcomes was conducted from
February to April 2011. Patients were classified as having received no previous treatment for TB or as having
received previous treatment(s) for TB. The World Health Organization (WHO) standard definitions were
used to MDR-TB, XDR-TB and treatment outcome (treatment success, died, failure, default and transferred
out) [1, 2]. Was analysed the relationship between treatment outcome and clinical and demographic factors.
It were also identified the predictors of poor outcome in a population of M/XDR-TB patients. The
association between explanatory variables and treatment outcome was evaluated by logistic regression
models. The crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were determined.
We assessed MDR-TB treatment outcomes in 364 patients (257 with MDR-TB and 107 with XDR-TB),
while 11 (3%) patients had no recorded final outcome (transferred out). The median age of the patients was
40 years (range: 13–86) and 259 (71.2%) patients were male. The amount of the patients that were HIV-
positive was 108 (30.5%). The proportion of cases resistant to all first-line anti-TB drugs was 19.2%. Results
of drug susceptibility testing (DST) to second-line drugs (amikacin, kanamycin, capreomycin, ofloxacin,
ciprofloxacin, cycloserine, ethionamide, para-aminosalycilic acid, thiacetazone) were analysed. Patients with
MDR-TB had a median resistance to four drugs (with a range of 2–10) and those with XDR-TB had a
median resistance to eight drugs (with a range 4–10) (p,0.001). The assessment of treatment outcomes
revealed that 42 (11.5%) patients were cured, 184 (50.5%) completed treatment, 92 (25.3%) died, 21 (5.8%)
experienced treatment failure, and 25 (6.9%) defaulted treatment. Thus, 226 (62.1%) patients achieved a
successful outcome. The treatment success rate was significantly different for patients who were never
treated for TB and for patients who received previous TB treatment (68% versus 54%; p50.01), and
between patients with MDR-TB and XDR-TB (66% versus 52%; p50.018).
Univariate analysis indicated that treatment outcome was significantly associated with injection drug use
only (OR 3.34, 95% CI 1.53–7.31; p50.003), alcohol abuse and injection drug use (OR 10.56, 95% CI
1.21–92.25; p50.033), HIV-positive status (OR 3.38, 95% CI 2.11–5.42; p,0.001), previous TB treatment
(OR 1.76, 95% CI 1.25–2.70; p50.010), resistance to kanamycin alone (OR 1.89, 95% CI 1.20–2.99;
p50.006), and XDR-TB (OR 1.78, 95% CI 1.13–2.82; p50.014) (table 1).
The considered multiple logistic regression model included HIV-positive status, previous TB treatment and
resistance to kanamycin alone as independent variables. This model indicated that HIV-positive status
(adjusted OR 3.56, 95% CI 2.20–5.77; p,0.001), previous TB treatment (adjusted OR 1.72, 95% CI
1.08–2.74; p50.023), and resistance to kanamycin alone (adjusted OR 1.68, 95% CI 1.02–2.75; p50.013)
were significant risk factors for poor treatment outcome (table 1).
In the present study, the overall treatment success rate was 62%, which is higher than the global success rate
of 48% estimated by WHO [1], and is similar to the success rates reported for other individual countries
(62%) [3, 4] In the current study’s population, poor outcome was related to the high case-fatality rate
(25%). The average case-fatality rates in other countries have been reported as 9% [4] and 11% [3]. The
high case fatality in our study may be explained by the high prevalence of HIV-positive patients (30.5%).
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Mortality among patients with MDR-TB HIV-positive was 44%. The risk of poor outcome in our HIV-
positive patients (31%) was 3.6 times higher than in HIV-negative patients.
We found significant differences in treatment outcomes of new MDR-TB patients and patients who had
previous treatment for TB (68% versus 55%; p50.013), and that the presence of previous TB treatment was
an independent risk factor for poor outcome. In the group of previously treated patients 30% of them died
during treatment and 39% of these patients were HIV- positive. It is also noteworthy that 57% of MDR-TB
patients in our study had never been treated for TB. The high prevalence of new cases among MDR-TB
cases could be attributed to the transmission of drug-resistant strains of Mycobacteria tuberculosis in our
population. Molecular fingerprinting is an important tool to understand better the role of acquired or
transmitted resistance among the relapsed patients with MDR and XDR-TB [5].
We also found a significant difference in the therapeutic success of MDR-TB patients and XDR-TB patients
(66% versus 52%, p50.018). The proportion of XDR-TB cases in our population was 29.4%, but XDR-TB
was not significantly associated with a poor outcome. However, resistance to kanamycin alone was an
indicator of poor prognosis. It should be noted that 109 (30%) cases in our study were resistant to
TABLE 1 Predictors of poor outcome among 364 patients with multidrug-resistant (MDR) tuberculosis (TB)
Predictors Treatment success Poor
outcome
Univariate analysis Multivariate analysis
OR# (95% CI) p-value OR# (95% CI) p-value
Patients n 226 138
Age years
o40 111 (49.1) 76 (55.1) 1.0
,40 115 (59.2) 62 (44.9) 0.79 (0.52–1.20) 0.270
Sex
Female 73 (32.3) 32 (23.2) 1.0
Male 153 (67.7) 106 (76.8) 1.58 (0.97–2.56) 0.064
Country of birth
Portugal 184 (81.4) 107 (77.5) 1.0
Foreign 42 (18.6) 31 (22.5) 1.27 (0.75–2.14) 0.370
Risk factors"
None 133 (62.1) 63 (48.8) 1.0
Alcohol abuse only 39 (18.2) 22 (17.1) 1.19 (0.65–2.17) 0.570
Injection drug use only 12 (5.6) 19 (14.7) 3.34 (1.53–7.31) 0.003
Alcohol abuse and injection
drug use
1 (0.5) 5 (3.9) 10.56 (1.21–92.25) 0.033
Other 29 (13.6) 20 (15.5) 1.46 (0.77–2.77) 0.253
HIV status+
Negative 174 (79.5) 72 (53.3) 1.0 1.0
Positive 45 (20.5) 63 (46.7) 3.38 (2.11–5.42) ,0.001 3.56 (2.20–5.77) ,0.001
Treatment history
Never treated for TB 141 (62.4) 67 (48.6) 1.0 1.0
Previously treated for TB 85 (37.6) 71 (51.4) 1.76 (1.15–2.70) 0.010 1.72 (1.08–2.74) 0.023
Site of disease
Pulmonary 211 (93.4) 123 (89.1) 1.0
Pulmonary and
extra-pulmonary
15 (6.6) 15 (10.9) 1.72 (0.81–3.63) 0.158
Chest radiograph1
No cavitation 115 (55.6) 55 (45.8) 1.0
Cavitation 92 (44.4) 65 (54.2) 1.48 (0.94–2.32) 0.090
Resistance to kanamycin
No 170 (75.2) 85 (61.6) 1.0 1.0
Yes 56 (24.8) 53 (38.4) 1.89 (1.20–2.99) 0.006 1.68 (1.02–2.75) 0.040
Categories of drug resistance
MDR 170 (75.2) 87 (63.0) 1.0
XDR 56 (24.8) 51 (37.0) 1.78 (1.13–2.82) 0.014
Data are presented as n (%) unless otherwise stated. XDR: extensively drug-resistant. #: crude and adjusted odds ratio (OR) for poor outcome; ":
treatment success n5214 and poor outcome n5129; +: treatment success n5219 and poor outcome n5135; 1: treatment success n5207 and poor
outcome n5120.
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kanamycin, as well as 90 (83%) kanamycin-resistant cases had XDR-TB. MIGLIORI et al. [6] suggested that
resistance to capreomycin, in particular, significantly increased the risk of death and treatment failure in M/
XDR-TB cases, but that resistance to either kanamycin or amikacin alone did not significantly increase the
risk of poor prognosis. In the largest cohort study ever published, no single drug was associated with
treatment success in cases resistant to fluoroquinolones and in XDR-TB cases [4, 7].
Our study has several limitations due to its retrospective design. According to the Directorate-General of
Health report in Portugal between 2000 and 2009 the coverage of DST to first-line drugs was of 69% [8].
Therefore, the number of MDR-TB cases within that period was probably underestimated. In our study
23% of cases had no results of DSTs to second-line drugs. In addition we only analysed a limited number of
factors because we were only able to consider factors that were in the form of a notification. Despite these
limitations, our study was the first nationwide study in Portugal to evaluate treatment outcomes of patients
with MDR-TB, and to analyse the relationship between treatment outcome and various risk factors.
In conclusion, we found that the results of treatment for MDR-TB in Portugal are similar to the worldwide
situation during our study period. We observed that being HIV-positive, having a previous TB treatment or
resistance to kanamycin were independent risk factors for a poor outcome in our population.
The National Tuberculosis Program in Portugal was established in 1995, but it was only defined in 2007 as a
specific strategy to control MDR-TB [9], based on the WHO Global Plan to Stop TB 2006–2015. To
monitor the effectiveness of anti-M/XDR-TB interventions [10], similar evidence from other countries
is necessary.
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